U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C6H11O7.Cu
Molecular Weight 453.841
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of COPPER GLUCONATE

SMILES

[Cu++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O

InChI

InChIKey=OCUCCJIRFHNWBP-IYEMJOQQSA-L
InChI=1S/2C6H12O7.Cu/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1

HIDE SMILES / InChI
Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H11O7
Molecular Weight 195.1473
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

CNS Active
3913
Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Schweizer, J.
35
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 3.42 µM [Ki]
Ceruloplasmin
35
Target ID: P00450
Gene ID: 1356.0
Gene Symbol: CP
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Glutathione S-transferase, rat, liver
35
Target ID: Glutathione S-transferase, rat, liver
Binding Agent
1064
Modulator
828
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Preclinical
Unknown

Approved Use

Unknown
Preventing
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8429
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
Approved
8429
COPPER•MAX

Approved Use

Unknown
Primary
Not Provided
504
Unknown

Approved Use

Unknown
Preventing
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Diagnostic
Preclinical
Unknown

Approved Use

Unknown
Preventing
Approved
8429
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
Approved
8429
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Antioxidant activity of olive pulp and olive oil phenolic compounds of the arbequina cultivar.
2005 Mar 23
Cu(II) acetate- and Mn(III) acetate-mediated radical reactions of [60]fullerene with ketonic compounds.
2005 Mar 7
A spectroscopic and thermoanalytical study of the mineral hoganite.
2007 May
Bioavailability of copper from copper glycinate in steers fed high dietary sulfur and molybdenum.
2008 Jan
Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes.
2009 Jan 16
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.
2010 Feb 3
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.
2011 Apr
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
SILAC-based quantitative proteomic analysis of human lung cell response to copper oxide nanoparticles.
2014
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.
2014 Feb 26
CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin.
2015 Jun
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.
2017 Jun 15
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.
2017 May
Patents

Patents

04904671
36
05034547
35
06203724
35
07465750
39
08399460
35
08722671
35
US2006191376
35
US20090239073 A1
35
US20090269269
35
US20160374209
35
US2046937 A
35
US2460067 A
35
US2533245 A
35
US3900504 A
35
US4020180 A
35
US6579328
35
US6670494
35
US7053251 B2
35
US7402296
35
US8921591
35
WO2003052039A1
35
WO2014001924A1
35
WO2017019802A1
35
WO9806419
35

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Veterinary drug
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
In Vitro Use Guide
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:03:08 GMT 2023
Edited
by admin
on Fri Dec 15 15:03:08 GMT 2023
Record UNII
RV823G6G67
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COPPER GLUCONATE
FCC   HSDB   INCI   MART.   USP   VANDF   WHO-DD  
INCI  
Official Name English
CUPRUM GLUCONICUM
Common Name English
CUPRIC GLUCONATE [VANDF]
Common Name English
GLUCONIC ACID, COPPER(2+) SALT (2:1), D-
Common Name English
COPPER GLUCONATE [VANDF]
Common Name English
COPPER GLUCONATE [MART.]
Common Name English
CUPRIC GLUCONATE [MI]
Common Name English
COPPER (AS GLUCONATE)
Common Name English
GLUCONIC ACID, COPPER(2+) SALT
Common Name English
COPPER(II) GLUCONATE
Common Name English
COPPER(II)GLUCONATE
Common Name English
COPPER GLUCONATE [FCC]
Common Name English
COPPER GLUCONATE [USP MONOGRAPH]
Common Name English
COPPER GLUCONATE [INCI]
Common Name English
COPPER, BIS (D-GLUCONATO-O(SUP 1),O(SUP 2))-
Common Name English
COPPER D-GLUCONATE (1:2)
Common Name English
Copper gluconate [WHO-DD]
Common Name English
CUPRIC GLUCONATE
MI   VANDF  
Common Name English
COPPER(2+) D-GLUCONATE, (1:2)
Common Name English
COPPER GLUCONATE [HSDB]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 184.1260
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
FDA ORPHAN DRUG 522516
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
Code System Code Type Description
EVMPD
SUB13457MIG
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
FDA UNII
RV823G6G67
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
MERCK INDEX
m3900
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID4035960
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
RXCUI
2839
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
CONCEPT Dietary Supplement
SMS_ID
100000092221
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
HSDB
261
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
DRUG BANK
DB11246
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
PUBCHEM
10692
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
CAS
527-09-3
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-408-2
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
DAILYMED
RV823G6G67
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
NCI_THESAURUS
C80050
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
WIKIPEDIA
COPPER GLUCONATE
Created by admin on Fri Dec 15 15:03:08 GMT 2023 , Edited by admin on Fri Dec 15 15:03:08 GMT 2023
PRIMARY
Related Record Type Details
Structure of CUPRIC CATION
PARENT -> SALT/SOLVATE
Structure of GLUCONIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CUPRIC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966